Controversy Erupts Over Groundbreaking Opioid Addiction Study in Pregnant Women, Raising Questions of Research Integrity and Patient Safety

Knoxville, Tennessee – A highly publicized study by Dr. Craig Towers, a high-risk obstetrician, which purported to revolutionize the treatment of opioid addiction in pregnant women, has become the epicenter of a fierce debate within the medical community, raising serious allegations of ethical breaches and scientific misconduct. The study, published in the prestigious American Journal of Obstetrics and Gynecology (AJOG) in 2020, advocated for detoxing pregnant patients with naltrexone, a method that challenged long-standing medical protocols. However, an internal audit by the University of Tennessee Medical Center (UTMC) and subsequent concerns from addiction specialists have cast a long shadow over its findings, leading to calls for retraction and a wider examination of research oversight.

The Genesis of a Controversial Approach

Dr. Craig Towers arrived in Knoxville, Tennessee, in 2010, at the height of the region’s burgeoning opioid epidemic. Having practiced for a quarter-century in California and Wisconsin, Towers was immediately struck by the alarming number of pregnant women struggling with painkiller addiction and the tragic prevalence of newborns suffering from Neonatal Abstinence Syndrome (NAS) or Neonatal Opioid Withdrawal Syndrome (NOWS). These infants, often born inconsolable and experiencing severe withdrawal symptoms, required weeks of intensive, specialized care, becoming poignant symbols of a public health crisis that gripped Appalachia and beyond. Tennessee, in particular, was grappling with some of the highest rates of opioid prescriptions and related deaths in the nation, making the issue profoundly urgent.

Traditional medical doctrine for pregnant patients with opioid use disorder (OUD) emphasized maintenance therapy with opioid agonists like methadone or buprenorphine. While these medications control cravings and reduce overdose risk, they can still lead to NAS in newborns. The prevailing wisdom held that direct detoxification during pregnancy was too risky, potentially causing severe fetal stress, preterm labor, or even miscarriage. Towers, who joined UTMC’s high-risk pregnancy clinic and later the medical school faculty, began to question this established paradigm. Driven by what he perceived as a desperate need for alternative solutions, and inspired by the resilience of his patients, he embarked on a research journey to explore the safety and efficacy of detoxing pregnant women, specifically using naltrexone.

His initial investigations, collecting data on over 300 patients, appeared to challenge conventional wisdom. He posited that detoxing could be less harmful than feared, leading to "miracles" – babies born without withdrawal symptoms, a claim that garnered him significant media attention, including an interview with CNN’s Dr. Sanjay Gupta, and local recognition as a "Health Care Hero" by the Knoxville News Sentinel. Clinics across Tennessee and Florida began to adopt his pioneering approach, and in 2019, his medical school granted additional funding, praising his "many research efforts and leadership that has resulted in national recognition." Towers himself confidently declared at a university science forum that his findings were "going to revolutionize what we do."

A Groundbreaking Study Under Scrutiny

The culmination of Towers’ work was a study published in AJOG in 2020, titled "Use of Naltrexone in Treating Opioid Use Disorder in Pregnancy," involving 230 participants, with 121 receiving daily naltrexone. Unlike methadone or buprenorphine, naltrexone is an opioid antagonist, meaning it blocks opioid receptors, preventing the euphoric "high" and thus discouraging use. The study claimed naltrexone was effective in keeping most patients off opiates, and crucially, implied positive fetal outcomes.

However, the study’s results immediately raised eyebrows among addiction treatment specialists. Naltrexone, while a valuable tool in OUD treatment, had historically shown "lackluster results" in many other major studies, particularly regarding relapse prevention in non-pregnant populations. A systematic review of 13 studies, for instance, indicated average relapse rates of 72% among non-pregnant patients on oral naltrexone. The stark contrast between Towers’ seemingly exceptional success rates and established evidence prompted a group of eight specialists in addiction medicine and pregnancy to voice their concerns.

In July 2020, Dr. Mishka Terplan, an OB-GYN board-certified in addiction medicine and a contributor to federal guidelines for opioid use during pregnancy, penned a letter to the University of Tennessee. He expressed profound concern that the published article could cause "potential harm to a vulnerable population… through both ethically suspect clinical care and consequently misguided public health." This letter ignited a formal inquiry into Towers’ research practices.

Ethical Lapses and Institutional Findings

The specialists’ concerns were not unfounded. By the time their letter reached the university, an internal audit had already uncovered significant irregularities in Towers’ research methodology and oversight. The audit, conducted by the university and dated February 7, 2020, revealed a cascade of critical issues:

• Lack of Institutional Review Board (IRB) Approval: Towers failed to obtain the necessary IRB approval for the study, a fundamental requirement for all research involving human subjects. IRBs are multidisciplinary panels designed to protect the rights, safety, and welfare of research participants. Bypassing this crucial step is considered a major violation of research ethics.
• Inaccurate and Unverifiable Documentation: The audit found that Towers provided "inaccurate and/or unverifiable, contradictory source documentation" for a component of the study. This cast doubt on the integrity and reliability of the data presented.
• Missing Research Data: Towers did not provide the requested research databases or data analysis, making it impossible for auditors to independently verify his findings.
• Patient Confidentiality Concerns: Auditors were unable to ascertain the extent to which confidential patient health information was protected, raising additional ethical and legal questions.

These findings led the university’s IRB chair to issue a determination letter days after the audit’s completion, deeming the issues "serious noncompliance" and voting to suspend all of Towers’ open studies for safety reviews. A report was also filed with the federal Office for Human Research Protections (OHRP). Towers, however, voluntarily closed all research projects upon his retirement.

Towers, who retired from his faculty position in February 2020 (shortly after the audit began) and from clinical practice months later, cited health and family reasons for his departure. He vehemently disputed the audit’s conclusions, claiming auditors did not allow him a full opportunity to defend his work and that the journal’s subsequent decision to uphold the study was proof of its soundness.

The Human Cost: Patient Perspectives and Informed Consent

Beyond the methodological and ethical concerns, the human element of the study also came under scrutiny. Media coverage had often portrayed Towers as a compassionate physician, dedicated to helping women overcome addiction for the sake of their babies. However, the letter from the addiction specialists questioned whether "informed consent was not obtained or not properly obtained" from patients participating in the naltrexone research. This is particularly salient given that naltrexone in pregnancy was an experimental treatment.

Katie Carringer’s experience highlights these concerns. In 2018, Carringer, then six weeks pregnant and with a history of heroin addiction (though clean at the time), sought out Towers for high-risk pregnancy care and anxiety management. She told ProPublica she was surprised when Towers recommended naltrexone, a drug she knew from her work at a rehab facility was typically for individuals in the early stages of recovery and actively battling cravings. Despite her medical records indicating sustained sobriety and no prior drug use during her previous pregnancies, Carringer felt pressured to take the drug. She stopped after the first dose due to severe nausea, a common side effect, which her records confirmed.

Dr. Robert Klitzman, a bioethics expert at Columbia University, emphasized the critical importance of informed consent, especially when experimental treatments are involved. "You need to explain to people that there may be additional risk," he stated. Towers maintained that all study participants received a "notice of research" and consented, asserting, "I am not aware of any patient that felt pressured to participate."

Further raising alarms, University of North Carolina researcher Hendrée Jones, another signatory of the letter, found it highly unusual that the study reported only minor health problems among the mothers (nausea, headache) throughout their pregnancies. She noted that such a large cohort of pregnant patients with a history of opioid addiction would typically experience a wider range of serious medical events, making the study’s reported outcomes statistically improbable.

The Journal’s Response and Broader Implications

Despite the university’s audit findings and its explicit request for a retraction, the American Journal of Obstetrics and Gynecology (AJOG), published by Elsevier, took over three years to act. When it finally did in 2023, it issued a terse, 78-word "correction" rather than a full retraction. The correction merely stated that the study had been "improperly listed as a ‘prospective’ cohort study" and was, in fact, a "retrospective analysis of prospectively collected data."

This distinction is crucial in scientific research. Prospective studies follow patients in real time, collecting data forward from a baseline, offering higher reliability and better control over data collection, including tracking dropouts. Retrospective studies, conversely, look back at existing medical records. Towers himself had previously touted this naltrexone study as an improvement due to its "prospective" design.

Experts in research ethics and substance abuse during pregnancy, including those who spoke with ProPublica, universally condemned the journal’s response as insufficient. They argued that misrepresenting the methodology, particularly between prospective and retrospective designs, constitutes a significant breach of scientific integrity. "The misrepresentation is not minor," stated Eugenie Reich, an attorney specializing in research fraud, adding, "It runs throughout the piece."

Elsevier, the journal’s publisher, defended its decision, stating, "Based on the information available at the time, the Journal determined that a correction was appropriate to clarify the description of the study." Towers views the correction as vindication, asserting that AJOG would not retain the study in print if they did not believe it was IRB-approved after their review. However, the university’s audit explicitly found that the IRB approvals Towers provided to the journal did not apply to the study in question.

The reluctance of journals to retract studies, even when faced with institutional requests and evidence of serious noncompliance, is a recurring issue in scientific publishing. Less than 1 in 2,500 published studies are retracted, despite the potential damage to reputations and credibility. Ivan Oransky, co-founder of Retraction Watch, a site tracking scientific misconduct, highlighted this challenge, describing it as "the fox guarding the henhouse." He advocates for greater public accessibility of research misconduct reports, arguing they are fundamental to assessing the reliability of scientific findings.

The lingering presence of Towers’ unretracted study in the medical literature carries significant risks. During the years AJOG deliberated, the study was cited dozens of times by other researchers, potentially influencing clinical practice and public health policy regarding pregnant women with OUD. While Dr. Geogy Thomas, medical director of Dayspring Health in east Tennessee, praised Towers for "courageously challenged the status quo" and improving care, others, like obstetrician Dr. Cathleen Suto, who adopted a similar detox approach, found it ineffective in practice, with many patients failing to complete the weaning process.

The controversy surrounding Dr. Craig Towers’ study underscores the critical importance of robust research ethics, stringent institutional oversight, and transparent editorial accountability in scientific publishing. As Dr. Hendrée Jones succinctly put it, "When you make a mistake, you own up to that mistake and you fix it. And that paper is out there, and continues to be cited, and I see it." The unresolved questions about the study’s integrity leave a troubling legacy, potentially impacting patient care and eroding trust in the scientific process for a vulnerable population already facing immense challenges.